Peptides DB
Research-centric peptide and protocol reference hub
Study 5 of 5Cartalax (AED peptide) literatureNature medicineTop journal2025

Clinical validation of an AI-based blood testing device for diagnosis and prognosis of acute infection and sepsis.

Not reported in abstract.

Read at Nature medicineAdd to compare

Where it sits

this study against the rest of the cartalax (aed peptide) corpus
1
Preclinical
1
Observational
1
Open-label · this one
0
Randomised
2
Reviews

Summary and findings

Not reported in abstract.

How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2025

Abstract

The authors’ words, as Nature medicine supplied them

Lack of reliable diagnostics for the presence, type and severity of infection in patients presenting to emergency departments with non-specific symptoms poses considerable challenges. We developed TriVerity, which uses isothermal amplification of 29 mRNAs and machine learning algorithms on the Myrna instrument to determine likelihoods of bacterial infection, viral infection and need for critical care interventions within 7 days. To validate TriVerity, the SEPSIS-SHIELD study enrolled 1,222 patients with clinically adjudicated infection status and need for critical care intervention within 7 days as endpoints. The TriVerity Bacterial and Viral scores had higher accuracy than C-reactive protein, procalcitonin or white blood cell count for the diagnosis of bacterial infection with area under the receiver operating characteristic (AUROC) of 0.83, and viral infection (AUROC = 0.91). The TriVerity Severity score had an AUROC of 0.78 for predicting illness severity and allowed reclassification of risk for critical care interventions compared to clinical assessment (quick Sequential Organ Failure Assessment) alone. Each of the three scores had rule-in specificity >92% and rule-out sensitivity >95%. Comparison of antibiotics administration at presentation with post-follow-up adjudication found that TriVerity could potentially reduce false positives and false negatives for inappropriate antibiotics use by 60-70%. Further clinical testing in an interventional setting is needed to prove actionability and clinical benefit of TriVerity.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Cartalax (AED peptide) corpus

DRecent advances in dermal fibroblast senescence and skin aging: unraveling mechanisms and pioneering therapeutic strategies.Frontiers in pharmacology · 2025reviewCSeizure-related death exhibits a circadian rhythm independent of seizure timing or sleep in a mouse model of Dravet syndrome.The Journal of physiology · 2025 · Not reported in abstract.AnimalDTransport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers.europepmc · 2022reviewBGene expression in human mesenchymal stem cell aging cultures: modulation by short peptides.PubMed · 2020 · TERT gene expression increased eightfold in 'stationary' aging cultures.In vitro